Hundreds to Go

Pharmaceutical company Sanofi-Aventis is eliminating “hundreds of jobs,” reports Ed Silverman at Pharmalot. The cuts come in the wake of Sanofi’s acquisition of Genzyme, he say, adding that some R&D operations will be shuffled between its New Jersey and Massachusetts sites, and that there will be layoffs in sales, particularly in the cardiovascular and oncology groups.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.